Hims Wants to Keep Mailing You Copycat GLP-1s. It’s Getting Trickier.
About this episode
When a shortage of brand-name weight-loss drugs like Ozempic and Wegovy cleared the way for companies like Hims to fill the gap with cheaper, compounded versions, customers came flocking. But in February, the US Food and Drug Administration announced the shortage was over, leaving the company's strategy in flux and some investors worried.
On today’s Big Take podcast, host David Gura and Bloomberg healthcare reporter Madison Muller track how Hims became the king of copycat weight-loss drugs and what’s next for the company as it fights to hold onto the crown.
Read more: How Hims Became the King of Knockoff Weight-Loss Drugs
Cheap Ozempic Knockoffs Are Suddenly Everywhere. Are They Safe?
The Weight-Loss Drug Boom’s Prescription Problem
Listen and follow The Big Take on Apple Podcasts, Spotify or wherever you get your podcasts.
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time Big Take publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Big Take
So Could AI 'Kill Us All'?
Big Take
Trump Needs a Win. Enter His Venezuela Oil Deal
Big Take
Why the Bond Market Has Everyone On Edge
Big Take
Americans Are Spending Billions to Help Their Pets Live Longer
Big Take